NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
Clinical Trials
63 trialsNCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT02242942 2025-11-06
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT05105841 2025-10-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2 Completed
NCT02315768 2025-09-15
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
University of California, San Diego
Phase 1/2 Completed
NCT03039114 2025-08-21
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
Phase 1 Completed
NCT02558816 2025-07-24
OAsIs
Nantes University Hospital
Phase 1/2 Completed
NCT01995669 2025-06-24
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT04880863 2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03467373 2025-01-17
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
Phase 1 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT02569476 2024-10-26
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
BeiGene
Phase 1 Completed
NCT02529852 2024-09-19
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT04434196 2024-07-25
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene
Phase 1 Completed
NCT04313608 2024-03-25
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT04657302 2024-01-19
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT02417285 2023-10-23
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Celgene
Phase 1 Completed
NCT02611323 2023-10-10
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed
NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
NCT02962401 2023-08-29
RemodelWM3
French Innovative Leukemia Organisation
Phase 2 Completed
NCT03010358 2023-08-08
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT01992653 2023-03-14
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Genentech, Inc.
Phase 1/2 Completed
NCT02758665 2023-01-17
CLL2-GiVe
University of Ulm
Phase 2 Completed
NCT03276468 2023-01-10
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02257567 2022-11-14
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT04551352 2022-10-03
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Phase 1 Completed
NCT01332968 2022-08-11
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
Phase 3 Completed
NCT02877550 2022-06-10
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Swiss Cancer Institute
Phase 1 Completed
NCT02631577 2022-04-13
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT02968563 2022-01-21
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT02736617 2022-01-05
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02983617 2021-12-21
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT02406742 2021-09-20
ENHANCE
Celgene
Phase 1/2 Completed
NCT02596971 2021-05-24
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03755947 2021-02-02
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Phase 2 Completed
NCT02729896 2020-12-23
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed
NCT01671904 2020-10-14
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 1 Completed
NCT02055820 2020-06-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Hoffmann-La Roche
Phase 1/2 Completed
NCT02174172 2020-05-12
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02320487 2020-02-11
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT02071225 2020-02-07
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 2 Completed
NCT02220842 2020-01-27
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT01059630 2020-01-13
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc.
Phase 3 Completed